Agnieszka Biała is a Medical Science Liaison at Merck Canada, where she leads peer-to-peer scientific exchange across specialty portfolios (PAH, dyslipidemia), executes cross-functional advisory meetings, and synthesizes field intelligence to inform national portfolio strategies.

She brings over a decade of biopharmaceutical leadership across field medical strategy, commercial pipeline expansion, and academic research.

Previously, as a Business Development Manager in Precision Medicine at a global CRO, she expanded the multi-centre clinical trial footprint across gastrointestinal and metabolic indications (IBD, EoE, MASH, celiac), leading high-stakes bid defenses and global pipeline negotiations.

During her academic career in Canada, she collaborated with Health Canada and the Canadian Institutes of Health Research (CIHR) to evaluate post-market adverse drug reactions and independently spearheaded an international scientific conference.

She holds a PhD in Cardiovascular Pharmacology from the University of Helsinki, a Master of Pharmacy from the Medical University of Lodz, and a postgraduate diploma in Pharmacoeconomics, Marketing and Pharmaceutical Law from Warsaw University of Technology Business School.

Her motto is “Per aspera ad astra”.